Stockscreener 앱 받기
7.03
0.42%
-0.03
시간 외 거래:
7.03
Kamada Ltd 주식(KMDA)의 최신 뉴스
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving AverageTime to Sell? - MarketBeat
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving Average – Time to Sell? - Defense World
Kamada (KMDA) price target decreased by 11.86% to 13.26 - MSN
Kamada (KMDA) Stock Analysis Report | Financials & Insights - Benzinga
Kamada Ltd.(NasdaqGS: KMDA) added to NASDAQ Biotechnology Index - marketscreener.com
Is Kamada Ltd. stock affected by interest rate hikesInsider Selling & Long-Term Growth Plans - Улправда
Will Kamada Ltd. stock see insider buyingWeekly Trend Recap & Precise Entry and Exit Recommendations - Улправда
Is Kamada Ltd. stock positioned well for digital economyLayoff News & Fast Exit and Entry Strategy Plans - Улправда
Can Kamada Ltd. stock resist sector downturns2025 Top Gainers & Expert-Curated Trade Recommendations - DonanımHaber
Kamada announces $10M-$14M extension of Canadian supply tender - TipRanks
Can Kamada Ltd. stock rebound after recent weaknessIndex Update & Consistent Return Strategy Ideas - Улправда
Breakout Watch: Is Kamada Ltd. stock positioned well for digital economyJuly 2025 News Drivers & Growth Focused Entry Point Reports - Улправда
Kamada secures $10-14 million Canadian supply tender extension By Investing.com - Investing.com Nigeria
Kamada Ltd. Announces $10 Million to $14 Million Extension of Canadian Supply Tender - marketscreener.com
Kamada Receives Two-Year Supply Extension From Canadian Blood Services for Plasma-Derived Products - marketscreener.com
Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender - TipRanks
Kamada secures $10-14 million Canadian supply tender extension - Investing.com
Kamada (KMDA) announces $10–$14 million extension of Canadian tender - Stock Titan
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender - GlobeNewswire
Kamada Initiates Clinical Trial for CYTOGAM in Kidney Transplantation - MSN
Kamada shares drop as company halts Phase 3 study of inhaled AAT therapy - MSN
Breakout Zone: How geopolitical tensions affect Kamada Ltd stock2025 Earnings Surprises & Consistent Return Investment Signals - moha.gov.vn
Precision Trading with Kamada Ltd. (KMDA) Risk Zones - Stock Traders Daily
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
FY2025 Earnings Forecast for Kamada Issued By HC Wainwright - Defense World
What is HC Wainwright's Forecast for Kamada FY2025 Earnings? - MarketBeat
Sidoti Csr Comments on Kamada’s Q1 Earnings (NASDAQ:KMDA) - Defense World
HC Wainwright Has Bearish Outlook for Kamada FY2026 Earnings - Defense World
Kamada Ltd. Shareholders Approve Key Resolutions at Annual Meeting - TipRanks
Sidoti Csr Predicts Kamada's Q1 Earnings (NASDAQ:KMDA) - MarketBeat
H.C. Wainwright raises Kamada stock price target to $13 on strategic refocus - Investing.com Nigeria
H.C. Wainwright raises Kamada stock price target to $13 on strategic refocus By Investing.com - Investing.com South Africa
Why Is Kamada Stock Trading lower todayKamada (NASDAQ:KMDA) - Benzinga
Kamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall - marketscreener.com
Kamada discontinues Phase 3 inhaled AAT clinical trial - TipRanks
Kamada reiterates FY25 revenue guidance $178M-$182M - TipRanks
Kamada Discontinues Phase 3 Inhaled AAT Trial, Projects Growth in 2026 - TipRanks
Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Ant - GuruFocus
Kamada reiterates 2025 FY revenue guidance of $178M-$182M - marketscreener.com
Kamada Reiterates 2025 FY Revenue Guidance Of $178M-$182M - TradingView
Kamada stock tumbles after discontinuing Phase 3 Inhaled AAT trial By Investing.com - Investing.com Canada
Kamada stock tumbles after discontinuing Phase 3 Inhaled AAT trial - Investing.com
Kamada (NASDAQ: KMDA) drops inhaled AAT study, reaffirms $178M-$182M 2025 revenue - Stock Titan
Shareholders May Not Be So Generous With Kamada Ltd.'s (TLV:KMDA) CEO Compensation And Here's Why - simplywall.st
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Technical Reactions to KMDA Trends in Macro Strategies - news.stocktradersdaily.com
Kamada updates proxy statement ahead of annual shareholder meeting By Investing.com - Investing.com Australia
Kamada updates proxy statement ahead of annual shareholder meeting - Investing.com
2.19%
0.08%
자본화:
|
볼륨(24시간):